CN1465582A - Nucleotide analogs, medicinal compositions having same and use thereof - Google Patents
Nucleotide analogs, medicinal compositions having same and use thereof Download PDFInfo
- Publication number
- CN1465582A CN1465582A CNA021234698A CN02123469A CN1465582A CN 1465582 A CN1465582 A CN 1465582A CN A021234698 A CNA021234698 A CN A021234698A CN 02123469 A CN02123469 A CN 02123469A CN 1465582 A CN1465582 A CN 1465582A
- Authority
- CN
- China
- Prior art keywords
- oxygen
- methyl
- purine
- formamido
- positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 160
- 239000001301 oxygen Substances 0.000 claims description 160
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 86
- 150000002148 esters Chemical class 0.000 claims description 51
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 49
- -1 inorganic base salts Chemical class 0.000 claims description 47
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 37
- FFXFVWSZUMGPNE-UHFFFAOYSA-N ethoxymethylphosphonic acid Chemical class CCOCP(O)(O)=O FFXFVWSZUMGPNE-UHFFFAOYSA-N 0.000 claims description 36
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 34
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 229940094933 n-dodecane Drugs 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 159000000009 barium salts Chemical class 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 229910003002 lithium salt Inorganic materials 0.000 claims 2
- 159000000002 lithium salts Chemical class 0.000 claims 2
- 159000000003 magnesium salts Chemical class 0.000 claims 2
- 235000011164 potassium chloride Nutrition 0.000 claims 2
- 239000001103 potassium chloride Substances 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 4
- 239000003443 antiviral agent Substances 0.000 abstract description 3
- 241001493065 dsRNA viruses Species 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000003814 drug Substances 0.000 description 23
- 239000002585 base Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000001819 mass spectrum Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000011435 rock Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 4
- 101710142246 External core antigen Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 229960004117 capecitabine Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108010051152 Carboxylesterase Proteins 0.000 description 2
- 102000013392 Carboxylesterase Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical class NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 208000004449 DNA Virus Infections Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000005155 Picornaviridae Infections Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses nucleotide analogues, their preparation method and application. These compounds can be used as antiviral drugs, including DNA virus and RNA virus.
Description
Technical field
The present invention relates to nucleotide analog and preparation method thereof and application
Background technology
The present invention relates to a compounds, nucleoside phosphoric acid ester, to virus of AIDS, dna virus such as hepatitis B virus and RNA viruses have very strong activity, because the strong polarity of its phosphate group of nucleoside phosphorylase class is difficult for seeing through gastrointestinal membranes, so phosphotidic obtains its prodrug.The medicine with treatment future that obtains is modified in all these esterifications at present, its chemical property is all unstable, therefore need modify the Nucleotide medicine from new approach, to improve existing drug bioavailability, improve distribution in its body, improve stability of drug and to reduce this class medicine gastrointestinal side effect as feeling sick, vomiting waits and renal toxicity.
Capecitabine is a fluorine pyrimidine aminomethyl formic ether compounds of Hoffmann-La Roche company exploitation, it is the Fluracil prodrug, external a few no cytotoxicity effect, but oral then can be successively after entering in the body in liver a kind of 60kDa Procaine esterase and the effect that is present in the cytidine deaminase in liver and the tumor tissues be converted into 5 '-deoxidation-5-fluorine cytidine and 5 '-'-Deoxy-5-fluorouridine.This two metabolite is non-activity still, and wherein the latter has only the hydrolytic action that is subjected to thymidine phosphine acidifying enzyme more just can finally generate 5 FU 5 fluorouracil, and then produces cellulotoxic effect.Though right thymidine phosphine acidifying enzyme can be multiple tissue expressions such as gi tract and normal breast, its cell concn is low than some human-like tumour, especially mammary cancer and colon cancer cell.This actual target administration effect of capecitabine and " tumour activation " character mean that its side effect will be significantly less than Fluracil.And II clinical trial phase result has really also confirmed the above-mentioned theory supposition: the bone marrow depression of capecitabine and alopecia toxicity are very low, though it reports that maximum side reactions comprise diarrhoea, feel sick, vomiting, stomatitis, fatigue and hand-sufficient syndromes etc., but these side effects are except that the latter, all the other are all than Fluracil few (little), and all side effects all are easy to handle and reverse, and most of symptoms often can also be died away.Capecitabine in April, 1998 successively obtain beautiful, add, the approval of state such as Switzerland, its indication is that standard chemotherapy pharmaceutical pack is drawn together the metastatic breast cancer that anthracene nucleus medicaments such as taxol and Dx are failed to respond to any medical treatment.
Inspired by this; carry out the carbalkoxyl modification by purine 6-bit amino or pyrimidine 4-bit amino to The compounds of this invention; to improve the physico-chemical property of parent drug, improve existing drug bioavailability and reduce this class medicine gastrointestinal side effect as feeling sick vomiting etc. and renal toxicity.Water-soluble and the fat-soluble all extreme differences of one of them parent compound (PMEA) of known The compounds of this invention, its fusing point has very high lattice energy greater than 250 ℃, and these character have had a strong impact on its bioavailability.By the acidylate to 6-amino, the amino of sealing had both reduced its lattice energy; it is fat-soluble to have improved medicine again, helps phosphonate group and combines with viscous protein in the stomach chamber, generates neutral ion pair mixture; mechanism by passive diffusion is passed lipid film, thereby improves its bioavailability.
In addition, compound disclosed in this invention is after human oral absorbs, can in human liver, the specificity Procaine esterase be isomerase A, be converted into active medicine, but can not be converted into active medicine (Drugs ofthe Future 1996,21 (4): 358-360), thereby produce actual liver guide effect by the foreign matter enzyme B of liver and other organ, improve the distribution of medicine in liver, medicine to other tissue or organ side effect as feel sick, vomiting and renal toxicity will obviously reduce.
Summary of the invention
The purpose of this invention is to provide a class ucleosides antiviral agent, these antiviral agents have stronger antiviral activity to RNA viruses and dna virus such as acquired immune deficiency syndrome (AIDS), hepatitis B virus.
Compound provided by the present invention is the salt of formula (I) compound and this compound thereof.
Formula (I)
Here: R
1And R
2Can be similar and different and be independently selected from OR
4, NH
2, NHR
5Or N (R
5)
2Deng group; In some cases, R
1And R
2Can be interconnected to form a cyclic group; Under the other situation, R
1And R
2Can with R
3Connect and remove to form a cyclic group.
R
3Expression C
1-C
20The group that straight or branched alkyl, these alkyl can be contained hydroxyl, oxygen, nitrogen, halogen atom replaces, and works as R
3Be CH (CH
2OR
6) CH
2The time, R
1And R
2Represent hydroxyl respectively, R
6It is a hydrolyzable ester group.
R
4Expression hydrogen, CH
2C (O) NR
5 2, CH
2C (O) OR
5, CH
2OC (O) R
5, CH
2OC (O) OR
5, CH (R
5) OC (O) OR
5, CH (R
5) OC (O) R
5(its steric configuration is R, S or RS), CH
2C (R
5) 2CH2OH, or CH
2OR
5, R
4Can also be saturated or undersaturated straight or branched C
1-C
20Alkyl, aryl or aralkyl, these groups can be contained hydroxyl, oxygen, nitrogen, the group of halogen atom replaces.
B is independently selected from following groups
Or
R
5Expression C
1-C
20Alkyl, aromatic base or aralkyl, these groups can be replaced by the group that contains hydroxyl, oxygen, nitrogen, halogen atom;
R
7Be selected from hydrogen, fluorine, methyl or trifluoromethyl.
The formed salt of The compounds of this invention, its character does not have particular restriction, when the phosphate of formula of the present invention (I) compound has one or 2 phosphorus carboxyls " to expose ", is used as the treatment time spent, can form salt with alkali.For example, form salt as sodium, potassium, lithium with basic metal; Salt with alkaline-earth metal such as barium or calcium formation; Salt with other metal such as magnesium or aluminium formation; Also can form salt, as the salt that forms with guanidine or triethylamine with organic bases; Also can form salt, as the salt that forms with Methionin or arginine with alkali ammonia acidic amino acid.
The method that provides a kind of production The compounds of this invention easily and effectively of the present invention second.Formula (I) compound can be by following path of preparing:
Fig. 1
As R
1, R
2=-OH, then formula (I) compound can be by following path of preparing.
Fig. 2
When base is VITAMIN B4, can prepare by the same method, be about to adenine nucleotide behind aceticanhydride/pyridine acetyl, then with chloro-formic ester in the presence of triethylamine, react the carbalkoxyl thing, afterwards deacetylation gets target compound in aqueous sodium hydroxide solution.
The compounds of this invention has the antiviral activity of nucleosides, is the medicine of activeconstituents with it, can be used for this class or prevention dna virus or picornavirus infection diseases associated.
In addition, in said medicine, can also contain one or more pharmaceutically acceptable carriers.Described carrier comprises the conventional thinner of pharmaceutical field, vehicle, and weighting agent, tackiness agent, wetting agent, disintegrating agent, absorption enhancer, tensio-active agent, absorption carrier, lubricants etc. can also add flavouring agent, sweeting agent etc. in case of necessity.
Medicine of the present invention can be made tablet, pulvis, granula, capsule, various ways such as oral liquid and injecting drug use.The medicine of above-mentioned each formulation all can be according to the ordinary method preparation of pharmaceutical field.
EmbodimentEmbodiment 1:6-isobutyl oxygen formamido--9-[2-[two (pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine (1-A)
In 100ml three neck round-bottomed flasks, add 2g 9-[2-[two (pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine is dissolved in the 10ml dry methylene chloride, and the ice bath cooling is down; add the 0.5g triethylamine, then add the 0.6g isobutyl chlorocarbonate, after raw material reaction is complete; water decomposition on the rocks; dilute hydrochloric acid is washed 1 time, washes drying 2 times; concentrate; silica gel column chromatography gets product 1.8g with the methylene dichloride wash-out, productive rate 78.3%.Mass spectrum (FAB) 602 (M+1).Ultimate analysis C
25H
40N
5O
10P calculated value: C49.92%, H6.66%, N11.65%, P5.19%.Measured value: C49.67%, H6.45%, N11.72%, P5.27%.
Prepare following compounds by the same method:
Positive butyloxy formylamido-the 9-[2-[two of 6-(pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine (2-A);
The positive penta oxygen formamido--9-[2-[two of 6-(pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine (3-A);
The just own oxygen formamido--9-[2-[two of 6-(pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine (4-A);
6-oxygen formamido--9-[2-[in positive heptan two (pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine (5-A);
The positive hot oxygen formamido--9-[2-[two of 6-(pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine (6-A);
6-oxygen formamido--9-[2-[in the positive ninth of the ten Heavenly Stems two (pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine (7-A) or
6-oxygen formamido--9-[2-[in the positive last of the ten Heavenly stems two (pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine (8-A).Embodiment 2:6-isobutyl oxygen formamido--9-[2-[two (the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine (1-B)
In 100ml three neck round-bottomed flasks, add 2g 9-[2-[two (the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine is dissolved in the 10ml dry methylene chloride, and the ice bath cooling is down; add the 0.5g triethylamine; then add 0.6 isobutyl chlorocarbonate, after raw material reaction is complete, water decomposition on the rocks; wash 2 times; drying concentrates silica gel column chromatography; get product 2.1g with the methylene dichloride wash-out, productive rate 87.6%.Mass spectrum (FAB) 606 (M+1).Ultimate analysis C
23H
36N
5O
12P calculated value: C45.62%, H5.95%, N11.57%, P5.12%.Measured value: C45.43%, H6.11%, N11.49%, P5.25%.
Prepared following compounds with method: the positive butyloxy formylamido-9-[2-[two of 6-(the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine (2-B); The positive penta oxygen formamido--9-[2-[two of 6-(the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine (3-B); The just own oxygen formamido--9-[2-[two of 6-(the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine (4-B); 6-oxygen formamido--9-[2-[in positive heptan two (the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine (5-B); The positive hot oxygen formamido--9-[2-[two of 6-(the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine (6-B); 6-oxygen formamido--9-[2-[in the positive ninth of the ten Heavenly Stems two (the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine (7-B) and 6-oxygen formamido--9-[2-[in the positive last of the ten Heavenly stems two (the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine (8-B).Embodiment 3:2-(6-isobutyl oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester (1-C)
In 100ml three neck round-bottomed flasks, add 2g 2-(VITAMIN B4-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester, be dissolved in the 10ml dry methylene chloride, the ice bath cooling adds the 0.5g triethylamine down, then adds the 0.6g isobutyl chlorocarbonate, after raw material reaction is complete, drying is washed in water decomposition on the rocks 2 times, concentrate, silica gel column chromatography gets product 1.6g with the methylene dichloride wash-out, productive rate 67.1%.Mass spectrum (FAB) 620 (M+1).Ultimate analysis C
24H
38N
5O
10P calculated value: C46.53%, H6.14%, N11.31%, P5.00%.Measured value: C46.78%, H6.02%, N11.48%, P5.21%.
Prepared following compounds with method:
2-(the positive butyloxy formylamido of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester (2-C);
2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester (3-C);
2-(the just own oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester (4-C);
2-(6-oxygen in positive heptan formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester (5-C);
2-(the positive hot oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester (6-C);
2-(6-oxygen in positive ninth of the ten Heavenly Stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester (7-C) and 2-(6-oxygen in positive last of the ten Heavenly stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester (8-C).Embodiment 4:2-(6-isobutyl oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester (1-D)
In 100ml three neck round-bottomed flasks, add 2g 2-(6-amido-9H purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester, be dissolved in the 10ml dry methylene chloride, the ice bath cooling adds the 0.5g triethylamine down, then adds the 0.6g isobutyl chlorocarbonate, after raw material reaction is complete, drying is washed in water decomposition on the rocks 2 times, concentrate, silica gel column chromatography gets target compound 1.7g with the methylene dichloride wash-out, productive rate 71.2%.Mass spectrum (FAB) 616 (M+1).Ultimate analysis C
26H
42N
5O
10P calculated value: C50.73%, H6.83%, N11.38%, P5.04%.Measured value: C50.87%, H6.64%, N11.25%, P5.19%.
Prepared following compounds with method:
2-(the positive butyloxy formylamido of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester (2-D);
2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester (3-D);
2-(the just own oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester (4-D);
2-(6-oxygen in positive heptan formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester (5-D);
2-(the positive hot oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester (6-D);
2-(6-oxygen in positive ninth of the ten Heavenly Stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester (7-D) and 2-(6-oxygen in positive last of the ten Heavenly stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester (8-D).Embodiment 5:2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (1-E)
The preparation of (1.2-the positive penta oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid dibenzyl ester
In 100ml three neck round-bottomed flasks, add 2g 2-(6-amido-9H purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid dibenzyl ester, be dissolved in the 10ml dry methylene chloride, the ice bath cooling adds the 0.5g triethylamine down, then adds the 0.7g n-amyl chlorocarbonate, after raw material reaction is complete, drying is washed in water decomposition on the rocks 2 times, concentrate, silica gel column chromatography gets target compound 1.9g with the methylene dichloride wash-out, productive rate 76.4%.Mass spectrum (FAB) 582 (M+1).
The preparation of (2.2-the positive penta oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid
1.5g 2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid dibenzyl ester, in the presence of 1.0g Pd/C (5%), the 5atm hydrogenolysis gets target compound 0.8g, productive rate 77.3%.Mass spectrum (FAB) 402 (M+1).Ultimate analysis C
15H
24N
5O
6P calculated value: C44.89%, H5.99%, N17.46%, P7.73%.Measured value: C45.12%, H5.72%, N17.35%, P7.87%.
Prepared following compounds with method:
2-(6-isobutyl oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (2-E);
2-(the positive butyloxy formylamido of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (3-E);
2-(the just own oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (4-E);
2-(6-oxygen in positive heptan formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (5-E);
2-(the positive hot oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (6-E);
2-(6-oxygen in positive ninth of the ten Heavenly Stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (7-E);
2-(6-oxygen in positive last of the ten Heavenly stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (8-E);
2-(6-n-undecane oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (9-E);
2-(6-n-dodecane oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (10-E) and
2-(6-n-hexadecane oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid (11-E).The preparation of embodiment 6:2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids (1-F) 1.2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids dibenzyl ester
In 100ml three neck round-bottomed flasks, add 2g 2-(6-amido-9H purine-9-yl) ethoxyl methyl phosphonic acids dibenzyl ester, be dissolved in the 10ml dry methylene chloride, the ice bath cooling adds triethylamine 0.5g down, then adds n-amyl chlorocarbonate 0.7g, after raw material reaction was complete, water decomposition on the rocks was washed 2 times, dry, concentrate, column chromatography gets target compound 2.1g with the methylene dichloride wash-out, productive rate 84.0%, mass spectrum (FAB) 568 (M+1).(2.2-the positive penta oxygen formamido-of 6--9H-purine-9-yl) ethoxyl methyl phosphonic preparation
2g 2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids dibenzyl ester, in the presence of 1.5g Pd/C (5%), the 5atm hydrogenolysis gets target compound 1.2g, productive rate 87.9%.Mass spectrum (FAB) 388 (M+1).Ultimate analysis C
14H
22N
5O
6P calculated value: C43.41%, H5.68%, N18.09%, P8.01%.Measured value: C43.70%, H5.47%, N17.82%, P7.86%.
Prepared following compounds with method:
2-(6-isobutyl oxygen formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids (2-F);
2-(the positive butyloxy formylamido of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids (3-F);
2-(the just own oxygen formamido-of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids (4-F);
2-(6-oxygen in positive heptan formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids (5-F);
2-(the positive hot oxygen formamido-of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids (6-F);
2-(6-oxygen in positive ninth of the ten Heavenly Stems formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids (7-F);
2-(6-oxygen in positive last of the ten Heavenly stems formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids (8-F);
2-(6-n-undecane oxygen formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids (9-F);
2-(6-n-dodecane oxygen formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids (10-F) and
2-(6-n-hexadecane oxygen formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids (11-F).Embodiment 7: The compounds of this invention is to the restraining effect of 2.2.15 emiocytosis HBsAg and HBeAg.
2.2.15 cell draws from air hospital Viral Laboratory, Guangzhou, with DMEM nutrient solution (GIBCO), nutrient solution adds 10% foetal calf serum, G418 100 μ g/ml (GIBCO), and 0.03% glutamine is transferred pH to 6.48 with 0.23%HePes.Take by weighing an amount of sample and add 0.2ml DMSO, add 3.79ml 2%DMEM fully after the dissolving and filter, degerming gets the pastille nutrient solution, with 0.06% trypsinase the 2.2.15 cell is dispersed into the individual cells suspension, by 3 * 10
4Cells/well concentration is inoculated in 96 orifice plates, uses the pastille nutrient solution after 2 days instead.With cytosis after 12 days, suct clear liquid and be ELISA and measure HBsAg, HBeAg, remaining cell is measured drug cell toxicity with mtt assay.
HBeAg HBsAg compound TC50 (μ m) ID50 (μ m) TI TC50 (μ m) ID50 (μ m) TI3-A 4.0 0.2 20 4.0 0.35 11.43-B 5.3 0.32 16.6 5.3 0.48 11.03-C 6 0.25 24 6 0.51 15.73-D 9 0.4 22.5 9 0.67 13.41-E 6.5 0.3 21.7 6.5 0.55 13.08-E 12 0.3 40.0 12 0.47 25.51-F 10 0.24 41.7 10 0.28 35.78-F 13.1 0.27 48.5 13.1 0.36 36.4TC50: medicine is to 2.2.15 cell half toxic concentration. IC50:the drug level that for HBsAg or HBeAg inhibiting rate is at 50% o'clock.
Claims (17)
1. formula (I) compound and this compound pharmacy acceptable salt
Formula (I)
In the formula, R
1And R
2Can be similar and different and be independently selected from OR
4, NH
2, NHR
5Or N (R
5)
2Deng group; R
1And R
2Can be interconnected to form cyclic group, perhaps a R
1And R
2With R
3Be connected to form a cyclic group;
R
3Expression C
1-C
20The group that straight or branched alkyl, these alkyl can be contained hydroxyl, oxygen, nitrogen, halogen atom replaces, and works as R
3Be CH (CH
2OR
6) CH
2The time, R
1And R
2Represent hydroxyl respectively, R
6It is a hydrolyzable ester group.
R
4Expression hydrogen, CH
2C (O) NR
5 2, CH
2C (O) OR
5, CH
2OC (O) R
5, CH
2OC (O) OR
5, CH (R
5) OC (O) OR
5, CH (R
5) OC (O) R
5(its steric configuration is R, S or RS), CH
2C (R
5)
2CH
2OH, or CH
2OR
5, R
4Be C
1-C
20The group that saturated or undersaturated straight or branched alkyl, aryl or aryl, these groups can be contained hydroxyl, oxygen, nitrogen or halogen atom replaces;
R
5Expression C
1-C
20Saturated or undersaturated straight or branched alkyl, aromatic base or aryl, these groups can be replaced by the group that contains hydroxyl, oxygen, nitrogen or halogen atom;
B is independently selected from following groups
Or
R
7Be hydrogen, fluorine, methyl or trifluoromethyl.
2. compound according to claim 1 is characterized in that it has following structural (II):
Formula (II)
R
1And R
2Define as claim 1; Y represents hydrogen, methyl, methylol, CH
2OX or replacement or do not replace low alkyl group are when Y is CH
2OX, R
1And R
2Can independently be selected from hydroxyl; X is a hydrolysable group.
3. according to the described compound of claim 1, it is characterized in that described compound has following structural (III):
Formula (III)
R
8And R
9Can be identical or different and be independently selected from NR
12Or oxygen; R
10And R
11Can be identical or different and be independently selected from hydrogen or R
5R
12Represent hydrogen or low alkyl group; M and n can be identical or different and be independently selected from 0 or 1; B and R
5Such as claim 1 definition; Y such as claim 2 definition.
4. compound according to claim 2 is characterized in that described compound has following structural (IV) or (V):
Formula (IV)
Formula V
R wherein
1, R
2Definition according to claim 1.
5. compound according to claim 4 is characterized in that described compound is:
2-(6-isobutyl oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester;
2-(the positive butyloxy formylamido of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester;
2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester;
2-(the just own oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester;
2-(6-oxygen in positive heptan formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester;
2-(the positive hot oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester;
2-(6-oxygen in positive ninth of the ten Heavenly Stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester or 2-(6-oxygen in positive last of the ten Heavenly stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(the different third oxygen methanoyl) methyl] ester.
6. compound according to claim 4 is characterized in that described compound is:
2-(6-isobutyl oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester;
2-(the positive butyloxy formylamido of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester;
2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester;
2-(the just own oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester;
2-(6-oxygen in positive heptan formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester;
2-(the positive hot oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester;
2-(6-oxygen in positive ninth of the ten Heavenly Stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester or 2-(6-oxygen in positive last of the ten Heavenly stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid two [(new pentane acyloxy) methyl] ester.
7. compound according to claim 4 is characterized in that described compound structure is as follows:
2-(6-isobutyl oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid;
2-(the positive butyloxy formylamido of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid;
2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid;
2-(the just own oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid;
2-(6-oxygen in positive heptan formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid;
2-(the positive hot oxygen formamido-of 6--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid;
2-(6-oxygen in positive ninth of the ten Heavenly Stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid;
2-(6-oxygen in positive last of the ten Heavenly stems formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid;
2-(6-n-undecane oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid;
2-(6-n-dodecane oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid or
2-(6-n-hexadecane oxygen formamido--9H-purine-9-yl)-1 (R)-methyl ethoxy methyl-phosphorous acid.
8. compound according to claim 7, the salt that it is characterized in that described compound is pharmaceutically acceptable inorganic base salts.
9. compound according to claim 8 is characterized in that described inorganic base salts is sodium salt, sylvite, calcium salt, lithium salts, barium salt or magnesium salts.
10. 2 described compounds as requested is characterized in that described compound has following structural (VI):
Formula (VI)
R wherein
1, R
2Definition according to claim 1.
11., it is characterized in that described compound is according to the described compound of claim 10:
6-isobutyl oxygen formamido--9-[2-[two (pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine;
Positive butyloxy formylamido-the 9-[2-[two of 6-(pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine;
The positive penta oxygen formamido--9-[2-[two of 6-(pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine;
The just own oxygen formamido--9-[2-[two of 6-(pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine;
6-oxygen formamido--9-[2-[in positive heptan two (pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine;
The positive hot oxygen formamido--9-[2-[two of 6-(pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine;
6-oxygen formamido--9-[2-[in the positive ninth of the ten Heavenly Stems two (pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine or
6-oxygen formamido--9-[2-[in the positive last of the ten Heavenly stems two (pivalyl oxygen methoxyl group) phosphoryl methoxy base] ethyl] purine.
12., it is characterized in that described compound is according to the described compound of claim 10:
6-isobutyl oxygen formamido--9-[2-[two (the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine;
Positive butyloxy formylamido-the 9-[2-[two of 6-(the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine;
The positive penta oxygen formamido--9-[2-[two of 6-(the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine;
The just own oxygen formamido--9-[2-[two of 6-(the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine;
6-oxygen formamido--9-[2-[in positive heptan two (the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine;
The positive hot oxygen formamido--9-[2-[two of 6-(the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine;
6-oxygen formamido--9-[2-[in the positive ninth of the ten Heavenly Stems two (the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine or 6-oxygen formamido--9-[2-[in the positive last of the ten Heavenly stems two (the different third oxygen methanoyl methoxyl group) phosphoryl methoxy base] ethyl] purine.
13. compound according to claim 10 is characterized in that described compound is:
2-(6-isobutyl oxygen formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids;
2-(the positive butyloxy formylamido of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids;
2-(the positive penta oxygen formamido-of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids;
2-(the just own oxygen formamido-of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids;
2-(6-oxygen in positive heptan formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids;
2-(the positive hot oxygen formamido-of 6--9H-purine-9-yl) ethoxyl methyl phosphonic acids;
2-(6-oxygen in positive ninth of the ten Heavenly Stems formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids;
2-(6-oxygen in positive last of the ten Heavenly stems formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids;
2-(6-n-undecane oxygen formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids;
2-(6-n-dodecane oxygen formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids or
2-(6-n-hexadecane oxygen formamido--9H-purine-9-yl) ethoxyl methyl phosphonic acids.
14. compound according to claim 13, the salt that it is characterized in that described compound is pharmaceutically acceptable inorganic base salts.
15. compound according to claim 14 is characterized in that described inorganic base salts is sodium salt, sylvite, calcium salt, lithium salts, barium salt or magnesium salts.
16. an antiviral contains any one described compound of the claim 1 to 15 of significant quantity.
17. the application of any described compound in the claim 1 to 15 in the preparation anti-tumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021234698A CN1465582A (en) | 2002-07-01 | 2002-07-01 | Nucleotide analogs, medicinal compositions having same and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021234698A CN1465582A (en) | 2002-07-01 | 2002-07-01 | Nucleotide analogs, medicinal compositions having same and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1465582A true CN1465582A (en) | 2004-01-07 |
Family
ID=34142335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021234698A Pending CN1465582A (en) | 2002-07-01 | 2002-07-01 | Nucleotide analogs, medicinal compositions having same and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1465582A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009046573A1 (en) * | 2007-10-11 | 2009-04-16 | Beijing Shiqiao Bio-Pharmaceutical Co., Ltd | Liver targeting adefovir prodrug and its medical use |
| CN101003550B (en) * | 2006-12-30 | 2010-05-19 | 河南省分析测试研究中心 | 8-halogenated adenine nucleoside compound, its synthesis method and its pharmaceutical use |
| CN102228463B (en) * | 2005-06-13 | 2012-12-19 | 博瑞生物医药技术(苏州)有限公司 | Tenofovir crystals |
| CN101759720B (en) * | 2008-12-26 | 2013-01-23 | 上海信旗医药科技有限公司 | Acyclic nucleoside phosphonate compounds or pharmaceutically acceptable salts thereof, preparation method, application, intermediate compounds thereof, and medicinal composition containing same |
| CN103980318A (en) * | 2013-04-25 | 2014-08-13 | 刘沛 | Novel nucleoside phosphate prodrug containing substituted benzyl, preparation method and application thereof |
| CN105518011A (en) * | 2014-04-21 | 2016-04-20 | 四川海思科制药有限公司 | Method for preparing phosphoramidate derivative and intermediates thereof, and method for preparing intermediates |
| US9908908B2 (en) | 2012-08-30 | 2018-03-06 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Tenofovir prodrug and pharmaceutical uses thereof |
| JP2018517698A (en) * | 2015-05-29 | 2018-07-05 | 江蘇天士力帝益薬業有限会社Ｊｉａｎｇｓｕ Ｔａｓｌｙ Ｄｉｙｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Tenofovir monobenzyl ester phosphamide prodrug, its preparation and use |
| WO2018178722A1 (en) * | 2017-03-31 | 2018-10-04 | The University Of Liverpool | Prodrug compositions |
| CN110799192A (en) * | 2017-03-27 | 2020-02-14 | 加利福尼亚大学董事会 | Compositions and methods for treating cancer |
| CN115677774A (en) * | 2021-07-23 | 2023-02-03 | 上海医药工业研究院有限公司 | Phosphonate derivatives and their preparation and use |
| WO2024259930A1 (en) * | 2022-06-24 | 2024-12-26 | 润佳（苏州）医药科技有限公司 | Phosphonate compound and medical use thereof |
-
2002
- 2002-07-01 CN CNA021234698A patent/CN1465582A/en active Pending
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228463B (en) * | 2005-06-13 | 2012-12-19 | 博瑞生物医药技术(苏州)有限公司 | Tenofovir crystals |
| CN101003550B (en) * | 2006-12-30 | 2010-05-19 | 河南省分析测试研究中心 | 8-halogenated adenine nucleoside compound, its synthesis method and its pharmaceutical use |
| WO2009046573A1 (en) * | 2007-10-11 | 2009-04-16 | Beijing Shiqiao Bio-Pharmaceutical Co., Ltd | Liver targeting adefovir prodrug and its medical use |
| CN101759720B (en) * | 2008-12-26 | 2013-01-23 | 上海信旗医药科技有限公司 | Acyclic nucleoside phosphonate compounds or pharmaceutically acceptable salts thereof, preparation method, application, intermediate compounds thereof, and medicinal composition containing same |
| US9908908B2 (en) | 2012-08-30 | 2018-03-06 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Tenofovir prodrug and pharmaceutical uses thereof |
| CN103980318A (en) * | 2013-04-25 | 2014-08-13 | 刘沛 | Novel nucleoside phosphate prodrug containing substituted benzyl, preparation method and application thereof |
| CN105518011A (en) * | 2014-04-21 | 2016-04-20 | 四川海思科制药有限公司 | Method for preparing phosphoramidate derivative and intermediates thereof, and method for preparing intermediates |
| JP2018517698A (en) * | 2015-05-29 | 2018-07-05 | 江蘇天士力帝益薬業有限会社Ｊｉａｎｇｓｕ Ｔａｓｌｙ Ｄｉｙｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Tenofovir monobenzyl ester phosphamide prodrug, its preparation and use |
| US11260058B2 (en) | 2017-03-27 | 2022-03-01 | The Regents Of The University Of California | Compositions and method of treating cancer |
| CN110799192A (en) * | 2017-03-27 | 2020-02-14 | 加利福尼亚大学董事会 | Compositions and methods for treating cancer |
| EP3600329A4 (en) * | 2017-03-27 | 2020-12-30 | The Regents of The University of California | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER |
| US12427151B2 (en) | 2017-03-27 | 2025-09-30 | The Regents Of The University Of California | Compositions and method of treating cancer |
| CN110741009A (en) * | 2017-03-31 | 2020-01-31 | 利物浦大学 | prodrug composition |
| WO2018178722A1 (en) * | 2017-03-31 | 2018-10-04 | The University Of Liverpool | Prodrug compositions |
| US11498933B2 (en) | 2017-03-31 | 2022-11-15 | The John Hopkins University | Prodrug compositions |
| CN115677774A (en) * | 2021-07-23 | 2023-02-03 | 上海医药工业研究院有限公司 | Phosphonate derivatives and their preparation and use |
| CN115677774B (en) * | 2021-07-23 | 2025-04-22 | 上海医药工业研究院有限公司 | Phosphonate derivatives and preparation methods and uses thereof |
| WO2024259930A1 (en) * | 2022-06-24 | 2024-12-26 | 润佳（苏州）医药科技有限公司 | Phosphonate compound and medical use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2552931B1 (en) | Stereoselective synthesis of phosphorus containing actives | |
| US10695357B2 (en) | Methods for treating filoviridae virus infections | |
| CN1465582A (en) | Nucleotide analogs, medicinal compositions having same and use thereof | |
| KR20190141747A (en) | (S) -2-ethylbutyl 2-(((S)-(((2R, 3S, 4R, 5R) -5- (4-aminopyrrolo [2,1-f] [1,2,4] Crystalline form of triazine-7-yl) -5-cyano-3,4-dihydroxytetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate | |
| CZ20023051A3 (en) | Nucleoside analog and use thereof | |
| MX2007006961A (en) | 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation. | |
| JP2002536452A (en) | Phosphoramidates of (1R, cis) -4- (6-amino-9H-purin-9-yl) -2-cyclopentene-1-methanol as antivirals, and mono-, di- and triphosphates | |
| CN1265114A (en) | Method for large-scale production of Di (uridine 5'-tetraphosphate) and salts thereof | |
| CN104151360A (en) | Phosphoric acid/phosphonic acid derivatives and their medicinal uses | |
| WO2016155593A1 (en) | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | |
| WO2006029081A2 (en) | Nucleoside-lipid conjugates, their method of preparation and uses thereof | |
| CN104710477A (en) | Tenofovir cyclic phosphonate compound and pharmaceutically acceptable salt thereof, and preparation methods and applications thereof | |
| CN101450954B (en) | Nucleotide analogs and use thereof, and medicament composition containing nucleotide analogs | |
| CN1966514A (en) | Novel acyclic nucleoside phosphonate and its medical use | |
| AU2020333099B2 (en) | A prodrug platform useful to deliver amines, amides and phenols | |
| CN1465574A (en) | L-nucleoside derivative and use thereof | |
| JP2698460B2 (en) | Antitumor 6-sulfenamides, 6-sulfinamides and 6-sulfonamidopurines, purine nucleosides, purine nucleotides, and related compounds | |
| RU2104282C1 (en) | Nucleoside phospholipid derivatives and pharmaceutical composition | |
| Benckendorff | Chemical synthesis of fluorinated carbocyclic nucleoside analogues | |
| HK40035367A (en) | A remdesivir compound for use in treating nipah virus infections | |
| Nicholls | Synthesis and evaluation of some novel nucleotide derivatives as potential anti-AIDS drugs | |
| HK1181775B (en) | Stereoselective synthesis of phosphorus containing actives | |
| HK1199645B (en) | Stereoselective synthesis of phosphorus containing actives | |
| HK1232229B (en) | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | |
| UA73843C2 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |